HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Alessia Covre Selected Research

durvalumab

1/2021Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study.
2/2020Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival.
1/2018Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Alessia Covre Research Topics

Disease

25Neoplasms (Cancer)
03/2024 - 03/2007
20Melanoma (Melanoma, Malignant)
03/2024 - 05/2008
8Mesothelioma
01/2023 - 03/2013
7Testicular Neoplasms (Testicular Cancer)
12/2021 - 05/2008
6Brain Neoplasms (Brain Tumor)
03/2024 - 01/2017
2Glioblastoma (Glioblastoma Multiforme)
03/2024 - 07/2021
2Disease Progression
01/2021 - 04/2010
2COVID-19
01/2020 - 01/2020
2Malignant Mesothelioma
10/2019 - 01/2018
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
07/2021
1Lung Neoplasms (Lung Cancer)
01/2020
1Brain Diseases (Brain Disorder)
10/2019
1Neoplasm Metastasis (Metastasis)
01/2017
1Sarcoma (Soft Tissue Sarcoma)
03/2013
1Renal Cell Carcinoma (Grawitz Tumor)
03/2013
1Carcinogenesis
08/2007
1Neoplastic Cell Transformation
08/2007

Drug/Important Bio-Agent (IBA)

8AntigensIBA
12/2021 - 05/2008
7DNA (Deoxyribonucleic Acid)IBA
03/2024 - 08/2007
7guadecitabineIBA
03/2024 - 03/2013
6IpilimumabIBA
03/2024 - 12/2019
4MicroRNAs (MicroRNA)IBA
10/2022 - 06/2010
4Monoclonal AntibodiesIBA
10/2019 - 04/2010
3NivolumabIBA
03/2024 - 01/2021
3Immune Checkpoint InhibitorsIBA
03/2024 - 01/2020
3Biomarkers (Surrogate Marker)IBA
02/2024 - 01/2019
3Proteins (Proteins, Gene)FDA Link
11/2022 - 03/2013
3durvalumabIBA
01/2021 - 01/2018
3tremelimumabIBA
01/2021 - 01/2018
3Messenger RNA (mRNA)IBA
01/2018 - 03/2013
2dehydroacetic acid (DHAS)IBA
12/2019 - 01/2018
2DecitabineFDA Link
01/2018 - 03/2007
2AntibodiesIBA
10/2011 - 04/2010
1Histocompatibility Antigens Class IIIBA
03/2024
1W 12IBA
01/2024
1GSK-2816126IBA
11/2022
1NF-kappa B (NF-kB)IBA
11/2022
1Enhancer of Zeste Homolog 2 ProteinIBA
11/2022
1givinostatIBA
11/2022
1Histone Deacetylases (Histone Deacetylase)IBA
11/2022
1MethyltransferasesIBA
11/2022
1Tumor Biomarkers (Tumor Markers)IBA
10/2022
1Circulating MicroRNAIBA
10/2022
1Circular RNAIBA
01/2022
1tazemetostatIBA
12/2021
1fotemustine (Muphoran)IBA
01/2021
1B7-H1 AntigenIBA
02/2020
1Apoptosis Regulatory ProteinsIBA
02/2020
1Mitogen-Activated Protein KinasesIBA
01/2020
1RNA (Ribonucleic Acid)IBA
10/2019
1Immune Checkpoint ProteinsIBA
01/2019
1Cell-Free Nucleic AcidsIBA
01/2019
1Azacitidine (5 Azacytidine)FDA Link
01/2018
1InterferonsIBA
01/2018
1CytokinesIBA
01/2018
1Nucleosomes (Nucleosome)IBA
10/2013
1Histocompatibility Antigens Class IIBA
03/2013
1Cytidine DeaminaseIBA
03/2013
1Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA
03/2013
1antineoplaston A10 (A 10)IBA
03/2013
1NucleotidesIBA
05/2011
1ElementsIBA
05/2011
1Histones (Histone)IBA
06/2010
1EndoglinIBA
04/2010

Therapy/Procedure

20Immunotherapy
03/2024 - 03/2007
13Therapeutics
03/2024 - 06/2010
1Immunomodulation
01/2023
1Precision Medicine
10/2022
1Biological Therapy
07/2021
1Retreatment
01/2021
1Drug Therapy (Chemotherapy)
01/2018